{"id":2219,"date":"2015-08-24T00:00:00","date_gmt":"2015-08-24T00:00:00","guid":{"rendered":"http:\/\/www.pharma-mkting.comindex.php\/2015\/08\/24\/pinup-082415\/"},"modified":"2019-02-06T02:14:31","modified_gmt":"2019-02-06T02:14:31","slug":"pinup-082415","status":"publish","type":"post","link":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/articles\/news\/pinup-082415\/","title":{"rendered":"O Valeant! FDA is Approving Nearly ALL NMEs! Big Pharma vs Little Guy"},"content":{"rendered":"

Pharma Industry News Update<\/b>: 24 August 2015<\/p>\n\n

One Billion Dollars!
O Valeant!<\/i><\/b> Sung to tune of O Canada<\/i> <\/p>\n

Shortly after the FDA approved Addyi (the “pink pill”), Canadian pharma company Valeant announced it would buy Sprout for $1 billion. Was it a good buy? <\/p>\n

Firstly, where does a Canadian pharmaceutical company come up with one billion dollars? <\/p>\n

Secondly, how long will it take to recoup that and other costs associated with selling Addyi and start to make a profit?<\/p>\n

<\/p>\n

Read the Lyrics Here<\/a><\/p>\n

<\/p>\n\n

\"NewFDA’s Unbridled 96% New Drug Approval Rate<\/b> A New Record!
Remember when the FDA rejected drugs? <\/p>\n

We just got treated to a whole lot of drama this week as to whether Addyi, a drug to boost women’s libidos, would be approved. But based on the data, that approval was probably a foregone conclusion. <\/p>\n

As recently as 2008, companies filing applications to sell never-before-marketed drugs, which are referred to by the FDA as “new molecular entities,” faced rejection 66% of the time. Yet so far this year the FDA has rejected only three uses for new chemical entities, and approved 25, an approval rate of 89%. <\/p>\n

In reality, the FDA approval rate is more like 96%.<\/p>\n

Learn Why Here<\/a>
P.S. It’s no coincidence that this is happening as FDA sets its sights on PDUFA VI reauthorization<\/a>. <\/p>\n\n

Lilly’s “Intermittent Wiper” Moment<\/a><\/b> Accused of Stealing Drug Adherence Tool <\/p>\n

In its latest legal saga, the drugmaker is going head-to-head with a woman who claims that Lilly stole her idea for a tool that helps patients’ remember to take their meds. <\/p>\n

Plaintiff Lisa Duer filed a complaint alleging that Lilly at first tried to license her patented “Take-n-Slide” adherence gadget. But after the negotiations fell through, Lilly and its supplier, Bensussen Deutsch & Associates, simply copied Duer’s idea instead, the suit claims.<\/p>\n

This has all the dramatic BIG CORPORATION vs little guy overtones as in the 2008 movie Flash of Genius<\/i>, which focuses on Robert Kearns and his legal battle against the Ford Motor Company when they developed an intermittent windshield wiper based on the inventor’s ideas.\u00a0<\/p>\n

<\/p>\n

\u00a0Except that intermittent wiper blades really worked, whereas this “Take-n-Slide” adherence gadget probably won’t.<\/p>\n

<\/p>\n

Read More Here<\/a><\/p>\n

<\/p>\n\n

His and Hers Hand Towels Monographed with Viagra and Addyi Logos<\/b> Only $20!
$20.00\u00a0USD<\/p>\n

Overview<\/p>\n